Oragenics, Inc.
http://www.oragenics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oragenics, Inc.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Goldman Sachs Takes Holding In CRO Aragen Amid Outsourcing Impetus
Goldman Sachs backs CRO Aragen, which it believes is well placed to gain from the “secular trend” of an outsourcing uptick by biopharma. Aragen has a string of alliances and is also assisting with both vaccine and test kit development against SARS-CoV-2 for its customers.
Execs On The Move, July 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- OTC, Consumer
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice